ArticlePloS one2014
Von Willebrand factor regulation in patients with acute and chronic cerebrovascular disease: a pilot, case-control study.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Trial
- Plasma von Willebrand Factor and ADAMTS13 Interact WithJournal of the American Heart Association · 2026Article
- Von Willebrand Factor Antigen Levels Predict Poor Outcomes in Patients With Stroke and Cancer: Findings From the Multicenter, Prospective, Observational SCAN Study.Journal of the American Heart Association · 2024Article
- Coagulation biomarkers for ischemic stroke.Research and practice in thrombosis and haemostasis · 2023Article
- Observational
- The von Willebrand Factor A1 domain mediates thromboinflammation, aggravating ischemic stroke outcome in mice.Haematologica · 2021Article
- Neurovascular Unit as a Source of Ischemic Stroke Biomarkers-Limitations of Experimental Studies and Perspectives for Clinical Application.Translational stroke research · 2020Review
- The Association Between Vascular Inflammation and Depressive Disorder. Causality, Biomarkers and Targeted Treatment.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Changes in Plasma von Willebrand Factor and Cellular Fibronectin in MRI-Defined Traumatic Microvascular Injury.Frontiers in neurology · 2019Article
- Cellular stress induces erythrocyte assembly on intravascular von Willebrand factor strings and promotes microangiopathy.Scientific reports · 2018Article
- Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence.Thrombosis and haemostasis · 2018Review
- Current advances in circulating inflammatory biomarkers in atherosclerosis and related cardio-cerebrovascular diseases.Chronic diseases and translational medicine · 2017Article
- Clinical role of von Willebrand factor in acute ischemic stroke.Wiener klinische Wochenschrift · 2017Article
- Elevated Factor VIII and von Willebrand Factor Levels Predict Unfavorable Outcome in Stroke Patients Treated with Intravenous Thrombolysis.Frontiers in neurology · 2017Article
- The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy.Mediators of inflammation · 2017Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeIn animal models, von Willebrand factor (VWF) is involved in thrombus formation and propagation of ischemic stroke. However, the pathophysiological relevance of this molecule in humans, and its potential use as a biomarker for the risk and severity of ischemic stroke remains unclear. This study had two aims: to identify predictors of altered VWF levels and to examine whether VWF levels differ between acute cerebrovascular events and chronic cerebrovascular disease (CCD).
methodsA case-control study was undertaken between 2010 and 2013 at our University clinic. In total, 116 patients with acute ischemic stroke (AIS) or transitory ischemic attack (TIA), 117 patients with CCD, and 104 healthy volunteers (HV) were included. Blood was taken at days 0, 1, and 3 in patients with AIS or TIA, and once in CCD patients and HV. VWF serum levels were measured and correlated with demographic and clinical parameters by multivariate linear regression and ANOVA.
resultsPatients with CCD (158 ± 46%) had significantly higher VWF levels than HV (113 ± 36%, P<0.001), but lower levels than AIS/TIA patients (200 ± 95%, P<0.001). Age, sex, and stroke severity influenced VWF levels (P<0.05).
conclusionsVWF levels differed across disease subtypes and patient characteristics. Our study confirms increased VWF levels as a risk factor for cerebrovascular disease and, moreover, suggests that it may represent a potential biomarker for stroke severity, warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.